KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Net Cash Flow (2017 - 2025)

Historic Net Cash Flow for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $68.5 million.

  • Aquestive Therapeutics' Net Cash Flow rose 67215.5% to $68.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.2 million, marking a year-over-year decrease of 340.91%. This contributed to the annual value of $47.7 million for FY2024, which is 150176.42% up from last year.
  • Per Aquestive Therapeutics' latest filing, its Net Cash Flow stood at $68.5 million for Q3 2025, which was up 67215.5% from -$8.1 million recorded in Q2 2025.
  • In the past 5 years, Aquestive Therapeutics' Net Cash Flow ranged from a high of $71.3 million in Q1 2024 and a low of -$13.3 million during Q1 2022
  • Moreover, its 5-year median value for Net Cash Flow was -$2.9 million (2025), whereas its average is $5.1 million.
  • Over the last 5 years, Aquestive Therapeutics' Net Cash Flow had its largest YoY gain of 1834245.52% in 2024, and its largest YoY loss of 58274.89% in 2024.
  • Over the past 5 years, Aquestive Therapeutics' Net Cash Flow (Quarter) stood at -$3.1 million in 2021, then surged by 374.65% to $8.6 million in 2022, then tumbled by 112.12% to -$1.0 million in 2023, then tumbled by 507.37% to -$6.3 million in 2024, then surged by 1179.68% to $68.5 million in 2025.
  • Its Net Cash Flow stands at $68.5 million for Q3 2025, versus -$8.1 million for Q2 2025 and -$2.9 million for Q1 2025.